These are the Countries Where it's 'Legal' to Edit Human Embryos (Hint: the US is One)
By Lauren F Friedman,
Business Insider
| 04. 23. 2015
News broke on Wednesday that a team of Chinese scientists had edited the genes of human embryos for the first time ever, confirming long-swirling rumors that such ethically dicey experiments were underway and flouting recent calls to put a stop to them.
Around the world, the laws governing what's allowed when it comes to "editing the human germ line," the technical name for what the Chinese scientists did, are a mixed bag. That means that while the technology still has a long way to go before people can actually make genetically engineered babies, in many places there are no laws preventing a scary "Gattaca scenario," where designer babies become routine — just some loose guidelines and a variable sense of ethics.
Despite researchers urging caution — stating that this work needs to be "on hold pending a broader societal discussion of the scientific and ethical issues surrounding such use," an inventor of the technology that made it possible told National Geographic — it seems that while the Chinese scientists ruffled some feathers, they did not actually break...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...